Maryam Mooghali, Vinay K Rathi, Kushal T Kadakia, Joseph S Ross, Sanket S Dhruva
{"title":"医疗器械风险(再)分类:来自FDA 515计划倡议的教训","authors":"Maryam Mooghali, Vinay K Rathi, Kushal T Kadakia, Joseph S Ross, Sanket S Dhruva","doi":"10.1136/bmjsit-2023-000186","DOIUrl":null,"url":null,"abstract":"#### Key messages box The 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act granted the US Food and Drug Administration (FDA) regulatory authority over medical devices. Congress intended for FDA’s review requirements to correspond to the amount of information needed to provide ‘","PeriodicalId":33349,"journal":{"name":"BMJ Surgery Interventions Health Technologies","volume":"9 1","pages":"0"},"PeriodicalIF":2.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative\",\"authors\":\"Maryam Mooghali, Vinay K Rathi, Kushal T Kadakia, Joseph S Ross, Sanket S Dhruva\",\"doi\":\"10.1136/bmjsit-2023-000186\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"#### Key messages box The 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act granted the US Food and Drug Administration (FDA) regulatory authority over medical devices. Congress intended for FDA’s review requirements to correspond to the amount of information needed to provide ‘\",\"PeriodicalId\":33349,\"journal\":{\"name\":\"BMJ Surgery Interventions Health Technologies\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Surgery Interventions Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjsit-2023-000186\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Surgery Interventions Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjsit-2023-000186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Medical device risk (re)classification: lessons from the FDA’s 515 Program Initiative
#### Key messages box The 1976 Medical Device Amendments to the Food, Drug and Cosmetic Act granted the US Food and Drug Administration (FDA) regulatory authority over medical devices. Congress intended for FDA’s review requirements to correspond to the amount of information needed to provide ‘